Association of Circulating Very Long-Chain Saturated Fatty Acids With Cardiovascular Mortality in NHANES 2003-2004, 2011-2012
© The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society..
CONTEXT: Limited studies have shown a protective effect of very long-chain saturated fatty acids (VLSFAs) on healthy aging, diabetes, heart failure, and risk factors related to cardiovascular disease (CVD), but the role of VLSFAs on mortality risk is unclear.
OBJECTIVE: We aimed to investigate the association of serum docosanoic acid (C22:0) and serum lignoceric acid (C24:0) with all-cause and disease-specific mortality and to confirm the effect of VLSFAs on mortality risk in the whole, hyperlipidemia, and hypertensive populations.
METHODS: A total of 4132 individuals from the 2003-2004, 2011-2012 National Health and Nutrition Examination Survey (NHANES) were included in this study. There were 1326 and 1456 participants in the hyperlipidemia and hypertensive population, respectively. Mortality information was confirmed using the National Death Index (NDI). Multiple model calibration was performed using Cox regression analysis for known risk factors to explore the association between circulating VLSFAs and all-cause or CVD or coronary heart disease (CHD) mortality.
RESULTS: In the whole population, individuals with higher circulating C22:0 and C24:0 as a percentage of total serum fatty acid levels reduced the risks of mortality of all-cause (C22:0: HR = .409; 95% CI, 0.271-0.618; C24:0: HR = 0.430; 95% CI, 0.283-0.651), CVD (C22:0: HR = 0.286; 95% CI, 0.134-0.612; C24:0: HR = 0.233; 95% CI, 0.101-0.538), and CHD (C22:0: HR = 0.401; 95% CI, 0.187-0.913; C24:0: HR = 0.263; 95% CI, 0.082-0.846). Similar to the whole population, individuals with higher circulating C22:0 and C24:0 as a percentage of total serum fatty acid levels in the hyperlipidemia and hypertensive populations were also protective for all-cause, CHD, and CVD mortality.
CONCLUSION: Our results confirm the protective effect of high levels of circulating VLSFAs (C22:0 and C24:0) on CVD, CHD, and all causes of death in the whole, hyperlipidemia, and hypertensive populations.
| Errataetall: |
ErratumIn: J Clin Endocrinol Metab. 2023 Nov 02;:. - PMID 37934859 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:109 |
|---|---|
| Enthalten in: |
The Journal of clinical endocrinology and metabolism - 109(2024), 2 vom: 18. Jan., Seite e633-e645 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tao, Xinmiao [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
All-cause mortality |
|---|
| Anmerkungen: |
Date Completed 19.01.2024 Date Revised 21.01.2024 published: Print ErratumIn: J Clin Endocrinol Metab. 2023 Nov 02;:. - PMID 37934859 Citation Status MEDLINE |
|---|
| doi: |
10.1210/clinem/dgad561 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362351015 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362351015 | ||
| 003 | DE-627 | ||
| 005 | 20240121231845.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1210/clinem/dgad561 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1266.xml |
| 035 | |a (DE-627)NLM362351015 | ||
| 035 | |a (NLM)37738581 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tao, Xinmiao |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Association of Circulating Very Long-Chain Saturated Fatty Acids With Cardiovascular Mortality in NHANES 2003-2004, 2011-2012 |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.01.2024 | ||
| 500 | |a Date Revised 21.01.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a ErratumIn: J Clin Endocrinol Metab. 2023 Nov 02;:. - PMID 37934859 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. | ||
| 520 | |a CONTEXT: Limited studies have shown a protective effect of very long-chain saturated fatty acids (VLSFAs) on healthy aging, diabetes, heart failure, and risk factors related to cardiovascular disease (CVD), but the role of VLSFAs on mortality risk is unclear | ||
| 520 | |a OBJECTIVE: We aimed to investigate the association of serum docosanoic acid (C22:0) and serum lignoceric acid (C24:0) with all-cause and disease-specific mortality and to confirm the effect of VLSFAs on mortality risk in the whole, hyperlipidemia, and hypertensive populations | ||
| 520 | |a METHODS: A total of 4132 individuals from the 2003-2004, 2011-2012 National Health and Nutrition Examination Survey (NHANES) were included in this study. There were 1326 and 1456 participants in the hyperlipidemia and hypertensive population, respectively. Mortality information was confirmed using the National Death Index (NDI). Multiple model calibration was performed using Cox regression analysis for known risk factors to explore the association between circulating VLSFAs and all-cause or CVD or coronary heart disease (CHD) mortality | ||
| 520 | |a RESULTS: In the whole population, individuals with higher circulating C22:0 and C24:0 as a percentage of total serum fatty acid levels reduced the risks of mortality of all-cause (C22:0: HR = .409; 95% CI, 0.271-0.618; C24:0: HR = 0.430; 95% CI, 0.283-0.651), CVD (C22:0: HR = 0.286; 95% CI, 0.134-0.612; C24:0: HR = 0.233; 95% CI, 0.101-0.538), and CHD (C22:0: HR = 0.401; 95% CI, 0.187-0.913; C24:0: HR = 0.263; 95% CI, 0.082-0.846). Similar to the whole population, individuals with higher circulating C22:0 and C24:0 as a percentage of total serum fatty acid levels in the hyperlipidemia and hypertensive populations were also protective for all-cause, CHD, and CVD mortality | ||
| 520 | |a CONCLUSION: Our results confirm the protective effect of high levels of circulating VLSFAs (C22:0 and C24:0) on CVD, CHD, and all causes of death in the whole, hyperlipidemia, and hypertensive populations | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a all-cause mortality | |
| 650 | 4 | |a cardiovascular mortality | |
| 650 | 4 | |a coronary heart mortality | |
| 650 | 4 | |a hyperlipidemia population | |
| 650 | 4 | |a hypertensive population | |
| 650 | 4 | |a very long-chain saturated fatty acids | |
| 650 | 7 | |a Fatty Acids |2 NLM | |
| 700 | 1 | |a Liu, Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Pingnan |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Jinxia |e verfasserin |4 aut | |
| 700 | 1 | |a Ming, Zhu |e verfasserin |4 aut | |
| 700 | 1 | |a Dang, Keke |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yuntao |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Ying |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of clinical endocrinology and metabolism |d 1945 |g 109(2024), 2 vom: 18. Jan., Seite e633-e645 |w (DE-627)NLM00001821X |x 1945-7197 |7 nnns |
| 773 | 1 | 8 | |g volume:109 |g year:2024 |g number:2 |g day:18 |g month:01 |g pages:e633-e645 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1210/clinem/dgad561 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 109 |j 2024 |e 2 |b 18 |c 01 |h e633-e645 | ||